-
Ice-cool Rybakina beats Sabalenka in tense Australian Open final
-
Pakistan attacks kill 15, dozens of militants dead: official
-
Ten security officials, 37 militants killed in SW Pakistan attacks: official
-
Epstein survivors say abusers 'remain hidden' after latest files release
-
'Full respect' for Djokovic but Nadal tips Alcaraz for Melbourne title
-
Wollaston goes back-to-back in the Cadel Evans road race
-
Women in ties return as feminism faces pushback
-
Ship ahoy! Prague's homeless find safe haven on river boat
-
Britain's Starmer ends China trip aimed at reset despite Trump warning
-
Carlos Alcaraz: rare tennis talent with shades of Federer
-
Novak Djokovic: divisive tennis great on brink of history
-
History beckons for Djokovic and Alcaraz in Australian Open final
-
Harrison, Skupski win Australian Open men's doubles title
-
Epstein offered ex-prince Andrew meeting with Russian woman: files
-
Jokic scores 31 to propel Nuggets over Clippers in injury return
-
Montreal studio rises from dark basement office to 'Stranger Things'
-
US government shuts down but quick resolution expected
-
Mertens and Zhang win Australian Open women's doubles title
-
Venezuelan interim president announces mass amnesty push
-
China factory activity loses steam in January
-
Melania Trump's atypical, divisive doc opens in theatres
-
Bad Bunny set for historic one-two punch at Grammys, Super Bowl
-
Five things to watch for on Grammys night Sunday
-
Venezuelan interim president proposes mass amnesty law
-
Rose stretches lead at Torrey Pines as Koepka makes cut
-
Online foes Trump, Petro set for White House face-to-face
-
Seattle Seahawks deny plans for post-Super Bowl sale
-
US Senate passes deal expected to shorten shutdown
-
'Misrepresent reality': AI-altered shooting image surfaces in US Senate
-
Thousands rally in Minneapolis as immigration anger boils
-
US judge blocks death penalty for alleged health CEO killer Mangione
-
Lens win to reclaim top spot in Ligue 1 from PSG
-
Gold, silver prices tumble as investors soothed by Trump Fed pick
-
Ko, Woad share lead at LPGA season opener
-
US Senate votes on funding deal - but shutdown still imminent
-
US charges prominent journalist after Minneapolis protest coverage
-
Trump expects Iran to seek deal to avoid US strikes
-
US Justice Dept releases documents, images, videos from Epstein files
-
Guterres warns UN risks 'imminent financial collapse'
-
NASA delays Moon mission over frigid weather
-
First competitors settle into Milan's Olympic village
-
Fela Kuti: first African to get Grammys Lifetime Achievement Award
-
Cubans queue for fuel as Trump issues oil ultimatum
-
'Schitt's Creek' star Catherine O'Hara dead at 71
-
Curran hat-trick seals 11 run DLS win for England over Sri Lanka
-
Cubans queue for fuel as Trump issues energy ultimatum
-
France rescues over 6,000 UK-bound Channel migrants in 2025
-
Surprise appointment Riera named Frankfurt coach
-
Maersk to take over Panama Canal port operations from HK firm
-
US arrests prominent journalist after Minneapolis protest coverage
US medical agency will scale back testing on monkeys
The United States will scale back certain drug-safety testing requirements on monkeys, federal regulators said Tuesday, marking the latest step by President Donald Trump's administration to limit the use of animals in research.
Under new draft guidance from the Food and Drug Administration, computer models, lab-grown mini-organs, and human studies will replace the use of non-human primates in testing monoclonal antibodies -- lab-engineered proteins used to treat cancers, autoimmune conditions and other diseases.
"We are delivering on our roadmap commitment to eliminate animal testing requirements in drug evaluation and our promise to accelerate cures and meaningful treatments for Americans," FDA Commissioner Marty Makary said in a statement.
The statement added that typical nonclinical programs involving monoclonal antibodies could include more than 100 macaque monkeys -- apes are no longer used in any invasive research in the US -- yet often do not yield human-approved treatments.
The move was welcomed by animal-advocacy groups.
Zaher Nahle, a former animal researcher who is now the senior scientific advisor for nonprofit Center for a Humane Economy, told AFP the move was an "important step."
"These primates are not reliable in terms of predicting the toxicity, so you can get at least equal or better results in terms of your accuracy in predicting toxicology using other approaches," he added.
What's more, he noted, studies show that more than 90 percent of drugs deemed safe and effective in animals fail to win approval for human use.
The FDA's announcement follows a report in the journal Science last month that the Centers for Disease Control and Prevention would close its primate labs.
It "moves us one step closer to wiping out the federal government's wasteful monkey business," Justin Goodman of White Coat Waste Project told AFP.
But the National Institutes of Health -- the country's primary biomedical research agency -- remains a notable "outlier," he added. According to public data, 7,700 primates are confined in federal government labs and breeding facilities, of which 6,700 are at NIH.
Advocates of animal research have pushed back.
"Poorly planned transitions -- including premature study termination -- can place animals at serious risk and may undermine years of scientific investment intended to strengthen public health preparedness and advance lifesaving medical progress," advocacy group Americans for Medical Progress said after the CDC news was reported.
Proponents of animal testing say the research has been indispensable for major medical advances, including vaccines for diphtheria, yellow fever, measles and Covid-19.
Critics counter that decades-old laws have created regulatory lock-in, that publication incentives reward animal studies in top journals, and that a lucrative "animal-industrial complex" has helped entrench the status quo.
D.Schneider--BTB